When: Confirmed close above $98-100 on >10M volume with MACD confirmation

Then: Bear setup invalidated; reconsider Underweight thesis

HOLD with modest 15-20% trim only on clean technical rejection at upper Bollinger Band (94.65) with volume

• Entry at 93.5 with stop at 103.76 represents 11% upside risk, not "essentially zero" downside
• Stock trades 5% below 52-week high of 106.33, with last close at 93.75
• Dividend yield of 3.07% is covered 1.4x by free cash flow
• 49 consecutive years of dividend increases with path to Dividend King in two years
• 5.4 billion in annual free cash flow backs the dividend
• Beta of 0.57 indicates defensive characteristics
• Upper Bollinger Band resistance at 94.65; 50 SMA support at 88.11
• Lower Bollinger and 50 SMA cluster near 89-90 proposed as proper stop level
• Recommended trim: 15-20%, not 30-40%
• Retain core income allocation rather than abandon position
• TAVR CMS coverage expansion provides structural CV portfolio tailwind
• 9.8 billion in revenue with broad-based acceleration across cardiovascular, neuroscience, and surgical

→ vs aggressive: Proposed 30-40% trim is excessive; 15-20% is sufficient given technical setup

→ vs aggressive: Stop at 103.76 (above 52-week high) is a profit-target exit, not a protective stop; provides zero risk containment

→ vs aggressive: Entry risk of 11% on the upside contradicts "essentially zero downside" framing

→ vs aggressive: MACD rollover may resolve higher (technical analyst acknowledged shallow pullbacks often do), exposing trim to whipsaw risk

→ vs aggressive: Sell timing coincides with Fed decision day and 10-year at 19-year high—concentrates timing risk on single binary event

→ vs aggressive: Q2 FY27 and MiniMed distribution are potential positives, not confirmed negatives; selling preemptively into unknown events is front-running the calendar

→ vs aggressive: T-bill yield comparison ignores dividend growth trajectory and equity multiple expansion potential on Fed cuts

→ vs aggressive: Peer comparison to Boston Scientific (cyberattack, Penumbra integration issues) and Intuitive (procedure growth slowdown) conflates company-specific issues with MDT's structural tailwinds

→ vs neutral: Buyback reduction reflects disciplined capital allocation amid higher rates, not management signaling stock overvaluation

Trim 20-25% of MDT position in phases; take 10-15% off now at 93-95, hold remainder contingent on technical signals; set protective stop at 88.50-89.00; profit target at 98-100; maintain core income allocation.

• Recommended trim of 20-25% in phases, not 15-20% (conservative) or 30-40% (aggressive)
• Execute 10-15% trim immediately into 93-95 zone while bid is present
• Retain trim capacity contingent on either MACD histogram staying negative below 92.00 breakdown or upper Bollinger rejection with volume on retest
• Protective stop on retained position at 88.50-89.00 (below 50 and 200 SMA cluster with ~1.5 ATR buffer of 2.31)
• Profit target at 98-100 aligns with November 2025 supply zone and psychological round number
• Stop at 103.76 is 11% above entry at 93.5—functions as profit target, not protective stop, creating no actual downside protection
• Support at 88 SMA cluster may fail; technical report notes negative histogram of -0.18 often resolves into shallow pullback or continuation higher
• Q1 FY27 organic growth of +13.7% included ~$570M from extra week but management raised full-year guidance showing underlying momentum acceleration above +8.4% FY26
• Forward P/E of 14.6x vs TTM of 23.1x shows market has already partially adjusted for normalization
• Buyback reduction from $3.24B to $1.04B reflects rational capital allocation given 19-year high 10-year yield and 94% probability of no Fed cuts in 2026, not necessarily a bearish signal
• Dividend maintained and covered 1.4x by free cash flow remains the actual shareholder commitment
• BSX and ISRG have company-specific issues not applicable to MDT's broad acceleration across cardiovascular, neuroscience, and surgical
• CMS TAVR coverage expansion is a structural tailwind for MDT not shared by peers
• MACD rollover at upper Bollinger after 28% rally is a real warning signal warranting exposure reduction, not full exit
• Defensive beta of 0.57 and underappreciated rerating thesis from Q1 beat and raised guidance support maintaining core income position
• Phased trimming hedges Fed day binary risk better than waiting or going all-in

→ vs aggressive: Stop at 103.76 is 11% above entry at 93.5—it's a profit target, not a protective stop, providing no actual downside protection and leaving the position fully exposed to declines

→ vs aggressive: "Essentially zero downside" is built on 88 SMA cluster support that technical analyst explicitly says may resolve into continuation higher, not a pullback

→ vs aggressive: Calendar distortion argument is used selectively—management raised guidance showing confidence the underlying momentum carries forward, not a fluke

→ vs aggressive: Forward P/E of 14.6x vs TTM of 23.1x shows market has already partially adjusted; you're fighting a position that has discounted some normalization

→ vs conservative: Plan to wait for clean rejection at 94.65 with volume may be too late—the stock already closed at 93.75 failing to break 94.65; rejection may have already happened

→ vs conservative: Waiting for confirmation risks trimming into weakness at 91 or 90 rather than harvesting gains at 93-95—worse entry and worse tax outcome

→ vs conservative: Stop at 89-90 with ATR of 2.31 gives only ~1.5 ATR buffer—tight enough that routine two-day volatility could shake you out before thesis plays out

→ vs conservative: "Selling into Fed day concentrates timing risk" actually argues for trimming now into the rally rather than waiting; either dovish (rip to 98) or hawkish (rates higher), phased trim hedges better